L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab

EGFR-specific tyrosine kinase inhibitors (TKIs), especially osimertinib, have changed lung cancer therapy, but secondary mutations confer drug resistance. Because other EGFR mutations promote dimerization-independent active conformations but L858R strictly depends on receptor dimerization, we herein...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrocco, Ilaria, Giri, Suvendu, Simoni-Nieves, Arturo, Gupta, Nitin, Rudnitsky, Anna, Haga, Yuya, Romaniello, Donatella, Sekar, Arunachalam, Zerbib, Mirie, Oren, Roni, Lindzen, Moshit, Fard, Damon, Tsutsumi, Yasuo, Lauriola, Mattia, Tamagnone, Luca, Yarden, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439256/
https://www.ncbi.nlm.nih.gov/pubmed/37557179
http://dx.doi.org/10.1016/j.xcrm.2023.101142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439256/
https://www.ncbi.nlm.nih.gov/pubmed/37557179
http://dx.doi.org/10.1016/j.xcrm.2023.101142

Ejemplares similares